ClinicalTrials.gg
CompletedNCT01885195SIGNATUREUpdated Feb 21, 2021Results posted

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

A Phase 2 interventional study of MEK162 in Solid Tumor and Hematologic Malignancies, sponsored by Pfizer. Completed at 68 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
132nd of 660
110 · median 40
Started
2013
with 30 others
Phase 2
194 of 823
25 open now
Registered
254th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 132nd largest by enrollment of the 660 interventional ones that give a count, is one of 31 that started in 2013, is one of 194 in phase 2, and was the 254th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Read the detailed description

This is a phase II, open label study to determine the efficacy and safety of treatment with MEK162 in patients with a diagnosis of select solid tumors or hematological malignancies that have been pre-identified (prior to study consent) to have activations of the RAS/RAF/MEK pathway and whose disease has progressed on or after standard treatment.

Genomic profiling is becoming more accessible to patients and their physicians. This is a signal-seeking study to match patients with mutations in RAF, RAS, NF1 or MEK to the ATP-noncompetitive MEK 1/2 inhibitor, MEK162. Pre-identification of these mutations or activations in the pathway will be performed locally at a CLIA certified laboratory prior to screening for participation on the trial.

Once the patient has been identified, treating physicians who are qualified investigators may contact Novartis to consider enrollment in this study. For the purpose of this study, genomic profiling is not considered part of screening. Informed consent must be signed before any screening activities take place. Once eligibility (screening criteria met) has been confirmed by Novartis, the patient will initiate therapy with single agent MEK162. The patient may not receive any additional anti-cancer therapy during treatment with MEK162.

Patients will continue to receive study treatment until disease progression (assessed by RECIST 1.1 or appropriate hematologic response criteria), unacceptable toxicity, death or discontinuation from study treatment for any other reason (e.g., withdrawal of consent, start of a new anti-neoplastic therapy or at the discretion of the investigator), otherwise known as End of Treatment. All patients who discontinue from study treatment due to disease progression must have their progression clearly documented.

Disease assessment (per RECIST 1.1 or appropriate hematological response criteria) will be performed every 8 weeks (±4 days) after first dose of study drug (Day 1 of every odd cycle), until disease progression or end of treatment, whichever occurs first. The frequency of disease assessment may be reduced to every 12 weeks for patients who have at least 4 post-baseline disease assessments and are clinically stable (except AML and MM patients). Scans will be assessed locally by the investigator. After discontinuation of treatment, patients, regardless of reason for treatment discontinuation, will be followed for safety for 30 days after the last dose.

All patients will be followed for survival status every 3 months for 2 years after the last patient has enrolled in the study regardless of treatment discontinuation reason (except if consent is withdrawn or patient is lost to follow-up.)

03

Conditions studied

  • Solid Tumor and Hematologic Malignancies

Keywords

  • RAS, RAF, MEK, NF1, MEK162, signature, papillary thyroid, small intestine, bladder, esophagus, lung cancer, NSCLC, acute myelogenous leukemia, AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a confirmed diagnosis of a select solid tumor (except for primary diagnosis of pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic (except for primary diagnosis of chronic myelomonocytic leukemia).
  • Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or MEK at a CLIA certified laboratory
  • Patient must have received at least one prior treatment for recurrent, and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
  • Patient must have progressive and as per 1.1. or other appropriate hematological guidelines.
  • Patient has an (ECOG) performance status ≤ 1

Exclusion criteria

Exclusion Criteria:

  • Patient has received prior treatment with MEK162.
  • Patients with primary CNS tumor or CNS tumor involvement
  • History of retinal degenerative disease
  • History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO)
  • Any ophthalmopathy visible at screening that would be considered a risk factor for CSR or RVO by the ophthalmologist
  • Patients who have neuromuscular disorders that are associated with elevated CK
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrollment
110 participants (actual)

Study arms

  • Experimental
    MEK162

    MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.

    Drug: MEK162

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    CBR: participants with complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than (\<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions.

    Time frame: Week 16

  2. CBR for Hematologic Tumors at Week 16: Multiple Myeloma

    CBR: participants with stringent complete response(sCR), CR, very good partial response(VGPR), PR/SD for at least 16 weeks. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on serum, urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow plus normal free light chain(FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry/immunofluorescence; CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and \<5% plasma cells in bone marrow; VGPR: serum,urine M-component detectable by immunofixation but not on electrophoresis or\>=90% reduction in serum M-component plus urine M-component \<100 mg/24 hr; PR: \>50% reduction of serum M-protein and reduction in 24hr urinary M-protein by \>90%/to \<200 mg/24 hr; SD: not meeting criteria for CR, VGPR, PRor PD; PD: increase of \>25% from lowest response value in serum M-component, urine M-component and bone marrow plasma cell percentage.

    Time frame: Week 16

  3. CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia

    CBR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\*10\^9/L and/or platelets ≥100\*10\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \< 5% of blasts contain auer rods, peripheral blood- neutrophils \<1.0\*10\^9/L and/or platelets \<100\*10\^9/L, no evidence of extramedullary disease; no response: in case a patient did not achieve CR, CRi, PR or relapse for an individual response assessment.

    Time frame: Week 16

Secondary outcomes

  1. Overall Response Rate (ORR) as Per RECIST Version 1.1

    ORR: percentage of participants with a best overall response (BOR) of CR or PR as assessed per RECIST version 1.1. BOR: the best response recorded from the start of the treatment until disease progression (PD). CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than \<10 mm; PR: at least a 30 % decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions.

    Time frame: From the start of the treatment until disease progression (maximum up to 19.4 months)

  2. ORR for Hematologic Tumors: Multiple Myeloma

    ORR: percentage of participants with sCR, CR, VGPR or PR. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on the serum, urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; CR: CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and \<5% plasma cells in bone marrow; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or greater than equal to \>=90% reduction in serum M-component plus urine M-component \<100 mg per 24hour (hr); PR: \>50% reduction of serum M-protein and reduction in 24 hr urinary M-protein by \>90% or to \<200 mg/24 hr.

    Time frame: From the start of the treatment until disease progression (maximum up to 19.4 months)

  3. ORR for Hematologic Tumors: Acute Myeloid Leukemia

    ORR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\*10\^9/L and/or platelets ≥100\*10\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \< 5% of blasts contain auer rods, peripheral blood- neutrophils \<1.0\*10\^9/L and/or platelets \<100\*10\^9/L, no evidence of extramedullary disease.

    Time frame: From the start of the treatment until disease progression (maximum up to 19.4 months)

  4. Progression-free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from the date of first dose to the date of first documented PD or relapse or death due to any cause. PD: at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions was also considered progression. PFS data was censored at date of last adequate tumor assessment.

    Time frame: From the date of first dose to the date of the first documented PD, censored date or death (maximum up to 19.4 months)

  5. Overall Survival (OS)

    OS was defined as the time from the date of first dose to the date of death due to any cause. If a participant was not known to have died, survival time was censored at the date of last contact.

    Time frame: From the date of first dose to the date of death due to any cause (maximum up to 19.4 months)

  6. Duration of Response (DOR) as Per RECIST Version 1.1

    DOR was defined as the time from the first documented response (CR or PR) to the date of first documented disease progression, relapse or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to \<10 mm; PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions. The DOR was determined only in participants whose best response was PR or greater.

    Time frame: From the first documented response (CR or PR) to the date of the first documented PD or death (maximum up to 19.4 months)

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03

    Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Treatment-emergent adverse events were defined as new or worsening events that were collected from first study treatment date to last treatment date +30 days. AEs of all grades were reported.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  8. Number of Participants With Vital Sign Abnormality of Greater Than or Equal to (>=) Grade 3 as Per CTCAE v4.03

    Vital signs included hypertension, hypotension and weight decreased were reported. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Participants with grade 3 or higher vital sign abnormality are reported.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  9. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcF) in millisecond (msec): greater than equal to (\>=) 450 to less than (\<) 480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60; 2) QTc interval adjusted according to Fridericia formula (QTcB) (msec): \>=450 to \<480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60. 3) QT (msec): \>=450 to \<480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  10. Number of Participants With Shift From Baseline in Clinical Laboratory - Hematology Parameters

    Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included neutrophils, platelets, prothrombin time, activated partial thromboplastin time, INR, fibrinogen. Number of participants with hematological abnormalities by grades (as per Common Terminology Criteria for Adverse Events (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  11. Number of Participants With Shift From Baseline in Clinical Laboratory - Biochemistry Parameters

    Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters included: creatinine, phosphorus, albumin, gamma-glutamyl transferase, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, total bilirubin, uric acid, amylase, lipase, creatine kinase, total cholesterol and triglycerides. Number of participants with biochemistry test abnormalities by grades (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  12. Number of Participants With Shift From Baseline in Cardiac Imaging

    Number of Participants With Shift From Baseline in Cardiac Imaging were reported.

    Time frame: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

07

Results

Posted Feb 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneBinimetinib (MEK162)
Started110
Completed0
Not completed110
Withdrew: Adverse event29
Withdrew: Death1
Withdrew: Disease progression67
Withdrew: Protocol deviation2
Withdrew: Physician decision3
Withdrew: Patient/guardian decision8

Outcome measures

PrimaryClinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

CBR: participants with complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than (\<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Percentage of participantsBinimetinib (MEK162)
Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.123.1 (15.4 to 32.4)
PrimaryCBR for Hematologic Tumors at Week 16: Multiple Myeloma

CBR: participants with stringent complete response(sCR), CR, very good partial response(VGPR), PR/SD for at least 16 weeks. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on serum, urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow plus normal free light chain(FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry/immunofluorescence; CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and \<5% plasma cells in bone marrow; VGPR: serum,urine M-component detectable by immunofixation but not on electrophoresis or\>=90% reduction in serum M-component plus urine M-component \<100 mg/24 hr; PR: \>50% reduction of serum M-protein and reduction in 24hr urinary M-protein by \>90%/to \<200 mg/24 hr; SD: not meeting criteria for CR, VGPR, PRor PD; PD: increase of \>25% from lowest response value in serum M-component, urine M-component and bone marrow plasma cell percentage.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
CBR for Hematologic Tumors at Week 16: Multiple Myeloma
Percentage of participantsBinimetinib (MEK162)
CBR for Hematologic Tumors at Week 16: Multiple Myeloma0.0 (0.0 to 70.8)
PrimaryCBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia

CBR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\*10\^9/L and/or platelets ≥100\*10\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \< 5% of blasts contain auer rods, peripheral blood- neutrophils \<1.0\*10\^9/L and/or platelets \<100\*10\^9/L, no evidence of extramedullary disease; no response: in case a patient did not achieve CR, CRi, PR or relapse for an individual response assessment.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia
Percentage of participantsBinimetinib (MEK162)
CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia33.3 (0.8 to 90.6)
SecondaryOverall Response Rate (ORR) as Per RECIST Version 1.1

ORR: percentage of participants with a best overall response (BOR) of CR or PR as assessed per RECIST version 1.1. BOR: the best response recorded from the start of the treatment until disease progression (PD). CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than \<10 mm; PR: at least a 30 % decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions.

Time frame:
From the start of the treatment until disease progression (maximum up to 19.4 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) as Per RECIST Version 1.1
Percentage of participantsBinimetinib (MEK162)
Overall Response Rate (ORR) as Per RECIST Version 1.12.9 (0.6 to 8.2)
SecondaryORR for Hematologic Tumors: Multiple Myeloma

ORR: percentage of participants with sCR, CR, VGPR or PR. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on the serum, urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; CR: CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and \<5% plasma cells in bone marrow; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or greater than equal to \>=90% reduction in serum M-component plus urine M-component \<100 mg per 24hour (hr); PR: \>50% reduction of serum M-protein and reduction in 24 hr urinary M-protein by \>90% or to \<200 mg/24 hr.

Time frame:
From the start of the treatment until disease progression (maximum up to 19.4 months)
Reported as:
Number · Percentage of participants
ORR for Hematologic Tumors: Multiple Myeloma
Percentage of participantsBinimetinib (MEK162)
ORR for Hematologic Tumors: Multiple Myeloma33.3 (0.8 to 90.6)
SecondaryORR for Hematologic Tumors: Acute Myeloid Leukemia

ORR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\*10\^9/L and/or platelets ≥100\*10\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \< 5% of blasts contain auer rods, peripheral blood- neutrophils \<1.0\*10\^9/L and/or platelets \<100\*10\^9/L, no evidence of extramedullary disease.

Time frame:
From the start of the treatment until disease progression (maximum up to 19.4 months)
Reported as:
Number · Percentage of participants
ORR for Hematologic Tumors: Acute Myeloid Leukemia
Percentage of participantsBinimetinib (MEK162)
ORR for Hematologic Tumors: Acute Myeloid Leukemia33.3 (0.8 to 90.6)
SecondaryProgression-free Survival (PFS) as Per RECIST Version 1.1

PFS was defined as the time from the date of first dose to the date of first documented PD or relapse or death due to any cause. PD: at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions was also considered progression. PFS data was censored at date of last adequate tumor assessment.

Time frame:
From the date of first dose to the date of the first documented PD, censored date or death (maximum up to 19.4 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Per RECIST Version 1.1
MonthsBinimetinib (MEK162)
Progression-free Survival (PFS) as Per RECIST Version 1.12.6 (1.9 to 3.5)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose to the date of death due to any cause. If a participant was not known to have died, survival time was censored at the date of last contact.

Time frame:
From the date of first dose to the date of death due to any cause (maximum up to 19.4 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsBinimetinib (MEK162)
Overall Survival (OS)8.5 (6.6 to 11.8)
SecondaryDuration of Response (DOR) as Per RECIST Version 1.1

DOR was defined as the time from the first documented response (CR or PR) to the date of first documented disease progression, relapse or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to \<10 mm; PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of \>=1 new target or non-target lesions. The DOR was determined only in participants whose best response was PR or greater.

Time frame:
From the first documented response (CR or PR) to the date of the first documented PD or death (maximum up to 19.4 months)
Reported as:
Median · Months
Duration of Response (DOR) as Per RECIST Version 1.1
MonthsBinimetinib (MEK162)
Duration of Response (DOR) as Per RECIST Version 1.1NA (NA to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03

Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Treatment-emergent adverse events were defined as new or worsening events that were collected from first study treatment date to last treatment date +30 days. AEs of all grades were reported.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03
ParticipantsBinimetinib (MEK162)
Grade 12
Grade 227
Grade 364
Grade 417
SecondaryNumber of Participants With Vital Sign Abnormality of Greater Than or Equal to (>=) Grade 3 as Per CTCAE v4.03

Vital signs included hypertension, hypotension and weight decreased were reported. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Participants with grade 3 or higher vital sign abnormality are reported.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormality of Greater Than or Equal to (>=) Grade 3 as Per CTCAE v4.03
ParticipantsBinimetinib (MEK162)
Hypertension15
Hypotension6
Weight Decreased11
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcF) in millisecond (msec): greater than equal to (\>=) 450 to less than (\<) 480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60; 2) QTc interval adjusted according to Fridericia formula (QTcB) (msec): \>=450 to \<480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60. 3) QT (msec): \>=450 to \<480, \>=480 to \<500, \>=500, increase from baseline \>=30, increase from baseline \>=60.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsBinimetinib (MEK162)
QTcF: >=450 to <480 msec15
QTcF: >=480 to <500 msec4
QTcF: >=500 msec1
QTcF: Increase from baseline >=30 msec20
QTcF: Increase from baseline >=60 msec3
QTcB: >=450 to <480 msec13
QTcB: >=480 to <500 msec5
QTcB: >=500 msec8
QTcB: Increase from baseline >=30 msec53
QTcB: Increase from baseline >=60 msec29
QT: >=450 to <480 msec13
QT: >=480 to <500 msec2
QT: >=500 msec2
QT: Increase from baseline >=30 msec39
QT: Increase from baseline >=60 msec7
SecondaryNumber of Participants With Shift From Baseline in Clinical Laboratory - Hematology Parameters

Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included neutrophils, platelets, prothrombin time, activated partial thromboplastin time, INR, fibrinogen. Number of participants with hematological abnormalities by grades (as per Common Terminology Criteria for Adverse Events (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Clinical Laboratory - Hematology Parameters
ParticipantsBinimetinib (MEK162)
Neutrophils6
Platelets3
Prothrombin Time2
Activated Partial Thromboplastin Time2
INR2
Fibrinogen0
SecondaryNumber of Participants With Shift From Baseline in Clinical Laboratory - Biochemistry Parameters

Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters included: creatinine, phosphorus, albumin, gamma-glutamyl transferase, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, total bilirubin, uric acid, amylase, lipase, creatine kinase, total cholesterol and triglycerides. Number of participants with biochemistry test abnormalities by grades (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Clinical Laboratory - Biochemistry Parameters
ParticipantsBinimetinib (MEK162)
Creatinine0
Phosphorus1
Albumin5
Gamma-Glutamyl Transferase1
Aspartate Transaminase2
Alanine Aminotransferase2
Alkaline Phosphatase0
Total Bilirubin0
Uric Acid0
Amylase2
Lipase5
Creatine Kinase18
Total Cholesterol0
Triglycerides1
SecondaryNumber of Participants With Shift From Baseline in Cardiac Imaging

Number of Participants With Shift From Baseline in Cardiac Imaging were reported.

Time frame:
From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Cardiac Imaging
ParticipantsBinimetinib (MEK162)
Number of Participants With Shift From Baseline in Cardiac Imaging10

Adverse events

Collected over From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Binimetinib (MEK162)—50/110 (45.5%)110/110 (100%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventBinimetinib (MEK162)
DyspnoeaRespiratory, thoracic and mediastinal disorders12/110
Abdominal painGastrointestinal disorders4/110
Small intestinal obstructionGastrointestinal disorders4/110
DehydrationMetabolism and nutrition disorders4/110
PneumoniaInfections and infestations3/110
Urinary tract infectionInfections and infestations3/110
HypoxiaRespiratory, thoracic and mediastinal disorders3/110
VomitingGastrointestinal disorders2/110
Oedema peripheralGeneral disorders2/110
PyrexiaGeneral disorders2/110
Most frequent other events
Showing 10 of 68
Most frequent other events
EventBinimetinib (MEK162)
FatigueGeneral disorders55/110
DiarrhoeaGastrointestinal disorders52/110
NauseaGastrointestinal disorders48/110
RashSkin and subcutaneous tissue disorders48/110
Oedema peripheralGeneral disorders44/110
VomitingGastrointestinal disorders42/110
Blood creatine phosphokinase increasedInvestigations38/110
AnaemiaBlood and lymphatic system disorders29/110
DyspnoeaRespiratory, thoracic and mediastinal disorders29/110
ConstipationGastrointestinal disorders25/110

Baseline characteristics

Full analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Binimetinib (MEK162)
Mean60.4 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Binimetinib (MEK162)
Female68
Male42
08

Study locations

68 sites
  • University of South Alabama / Mitchell Cancer Institute Univ South Alabama
    Mobile, Alabama 36688, United States
  • Alaska Oncology and Hematology AOH (2)
    Anchorage, Alaska 99508, United States
  • Arizona Oncology Associates AZ Oncology Assoc.
    Phoenix, Arizona, United States
  • Arizona Oncology Associates HOPE Division
    Phoenix, Arizona, United States
  • Arizona Oncology Associates PC- NAHOA
    Sedona, Arizona 86336, United States
  • Highlands Oncology Group Highlands Oncology Group (22)
    Fayetteville, Arkansas 72703, United States
  • PCR Oncology
    Pismo Beach, California 93449, United States
  • University of California Davis Cancer Center UC Davis Cancer (3)
    Sacramento, California 95817, United States
  • Rocky Mountain Cancer Centers USOR
    Boulder, Colorado 80304, United States
  • Yale University School of Medicine Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • Whittingham Cancer Center Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO
    Norwich, Connecticut 06360, United States
  • Hematology Oncology PC Stamford Hospital
    Stamford, Connecticut 06902, United States
  • Florida Cancer Specialists Florida Cancer Specialists (31
    Fort Myers, Florida 33901, United States
  • Memorial Cancer Institute Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Mt. Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Ocala Oncology Center Dept. of Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4
    Ocoee, Florida, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Lurie Children's Hospital of Chicago Developmental Therapeutics
    Chicago, Illinois 60611, United States
  • Oncology Specialists, SC Onc Specialists
    Park Ridge, Illinois 60068-0736, United States
  • Illinois Cancer Care IL. Cancer Care
    Peoria, Illinois 61615-7828, United States
  • Indiana University Indiana Univ. - Purdue Univ.
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals & Clinics Regulatory Contact 2
    Iowa City, Iowa 52242, United States
  • Maryland Oncology Hematology, P.A. Oncology Hematology
    Rockville, Maryland 20850, United States
  • Cancer and Hematology Centers of West Michigan Dept. of Oncology
    Grand Rapids, Michigan 49546, United States
  • Metro MN CCOP - Coon Rapids
    Coon Rapids, Minnesota 55433, United States
  • Research Medical Center Research Med Center (2)
    Kansas City, Missouri 64132, United States
  • Washington University School of Medicine Washington University (16)
    Saint Louis, Missouri 63110, United States
  • Glacier View Research Institute - Cancer Oncology Dept
    Kalispell, Montana 59901, United States
  • Comprehensive Cancer Centers of Nevada CCC of Nevada (21)
    Las Vegas, Nevada 89109, United States
  • Cancer Institute of New Jersey CINJ
    New Brunswick, New Jersey 08901, United States
  • New Mexico Cancer Care Alliance Oncology Dept
    Albuquerque, New Mexico 87106, United States
  • New York Oncology Hematology, P.C. NYOH Latham
    Troy, New York 12180, United States
  • University of North Carolina Chapel Hill Physician Office Building
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center Seeley G. Mudd Bldg.
    Durham, North Carolina 27710, United States
  • Sanford Research/USD-Fargo Sanford Hematology Oncology
    Fargo, North Dakota 58122, United States
  • Cleveland Clinic Foundation Cleveland Clinic (19)
    Cleveland, Ohio 44195, United States
  • Ohio State University Medical Center Comprehensive Cancer Center
    Columbus, Ohio 43221, United States
  • St. Charles Cancer Center
    Bend, Oregon 97701, United States
  • Willamette Valley Clinical Studies Cancer Institute & Res. Ctr.
    Eugene, Oregon 97404, United States
  • Northwest Cancer Specialists Vancouver Cancer Center
    Portland, Oregon 97210, United States
  • Oregon Health & Science University Oregon Health & Science U (56)
    Portland, Oregon 97239, United States
  • St. Luke's Hospital and Health Network St Luke's (2)
    Bethlehem, Pennsylvania, United States
  • West Penn Allegheny Oncology Network
    Natrona Heights, Pennsylvania 15065, United States
  • Abington Hematology Oncology Associates, Inc Abington Hem Onc Assoc (5)
    Willow Grove, Pennsylvania 19090, United States
  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
    Chattanooga, Tennessee 37404, United States
  • The West Clinic Dept. of the West Clinic
    Memphis, Tennessee 38120, United States
  • Sarah Cannon Research Institute Sarah Cannon Research Inst (51
    Nashville, Tennessee 37203, United States
  • Texas Oncology Presbyterian Hospital (3)
    Dallas, Texas 75246, United States
  • Texas Oncology Texas Oncology - Denton
    Dallas, Texas 75246, United States
  • Texas Oncology Austin Midtown
    Dallas, Texas 75251, United States
  • Texas Oncology Texas Oncology - Midland
    Dallas, Texas 75251, United States
  • Sammons Cancer Center - Texas Oncology Sammons Cancer Center (10)
    Dallas, Texas 78246, United States
  • Oncology Consultants Oncology Group
    Houston, Texas 77024, United States
  • MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
    Houston, Texas 77030, United States
  • Cancer Care Centers of South Texas / HOAST CCC of So. TX-San Antonio (3)
    San Antonio, Texas 78229, United States
  • Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
    Tyler, Texas 75702, United States
  • Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
    Webster, Texas 77598, United States
  • Intermountain Medical Center Intermountain Healthcare
    Murray, Utah 84157, United States
  • Virginia Cancer Specialists, PC Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA
    Reston, Virginia 20190, United States
  • Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc
    Kennewick, Washington 99336, United States
  • Providence Regional Cancer System
    Lacey, Washington 98503, United States
  • MultiCare Health System Institute for Research & Innovation MultiCare
    Tacoma, Washington 98405, United States
  • Northwest Medical Specialties NW Medical Specialties
    Tacoma, Washington 98405, United States
  • Medical College of Wisconsin Cancer Center
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043. PubMed 30181415 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Oct 2015, 23 months.

Results were first posted in Feb 2021, 5 years 4 months after primary completion. A results delay was requested in Nov 2016.

Of 136 phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 94. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2013
First posted
Jun 24, 2013
StartActual
Oct 10, 2013
Primary completionActual
Oct 1, 2015
CompletionActual
Apr 11, 2017
Results delay requested
Nov 9, 2016
Results first posted
Feb 21, 2021
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01885195
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Oct 10, 2013
Primary completion
Oct 1, 2015
Completion
Apr 11, 2017
Results posted
Feb 21, 2021
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Binimetinib

Start the discussion